NCT00117130

Brief Summary

The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 30, 2005

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 4, 2005

Completed
Last Updated

January 21, 2011

Status Verified

January 1, 2011

First QC Date

June 30, 2005

Last Update Submit

January 20, 2011

Conditions

Kidney Disease

Keywords

Kidney disease, Renal, CKD (Chronic Kidney Disease)CRI (Chronic Renal Insufficiency), Pre-dialysis, AmgenAranesp®, Darbepoetin alfa, QW dosingQ2W dosing, Q4W dosingPatient preference, Subject preference

Outcome Measures

Primary Outcomes (1)

  • Subject preference

Secondary Outcomes (1)

  • Subject productivity and subject selection of Aranesp® or Procrit® therapy in the parallel arm portion and at study conclusion.

Interventions

Aranesp®DRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

MeSH Terms

Conditions

Kidney DiseasesRenal Insufficiency, ChronicPatient Preference

Interventions

Darbepoetin alfa

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesRenal InsufficiencyChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsPatient SatisfactionTreatment Adherence and ComplianceHealth BehaviorBehavior

Intervention Hierarchy (Ancestors)

ErythropoietinColony-Stimulating FactorsGlycoproteinsGlycoconjugatesCarbohydratesProteinsAmino Acids, Peptides, and Proteins

Study Officials

  • MD

    Amgen

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 30, 2005

First Posted

July 4, 2005

Last Updated

January 21, 2011

Record last verified: 2011-01